Capstone Therapeutics Corp. (CAPS)
USD 2.08
(-11.49%)
USD 2.08
(-11.49%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.25 Million USD | -131.46% |
| 2022 | 3.99 Million USD | -13.87% |
| 2021 | 4.63 Million USD | 93.49% |
| 2020 | 2.39 Million USD | 414.44% |
| 2019 | -762 Thousand USD | -37.55% |
| 2018 | -554 Thousand USD | 67.02% |
| 2017 | -1.68 Million USD | -6.06% |
| 2016 | -1.58 Million USD | 46.1% |
| 2015 | -2.93 Million USD | 35.04% |
| 2014 | -4.52 Million USD | -5.38% |
| 2013 | -4.29 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 14 Thousand USD | 101.95% |
| 2024 Q1 | -717 Thousand USD | 26.01% |
| 2023 Q1 | -690 Thousand USD | -321.86% |
| 2023 Q3 | -149 Thousand USD | -126.99% |
| 2023 Q2 | 552 Thousand USD | 180.0% |
| 2023 FY | -1.25 Million USD | -131.46% |
| 2023 Q4 | -969 Thousand USD | -550.34% |
| 2022 Q1 | 56 Thousand USD | -81.7% |
| 2022 Q4 | 311 Thousand USD | -81.56% |
| 2022 Q3 | 1.68 Million USD | -13.0% |
| 2022 FY | 3.99 Million USD | -13.87% |
| 2022 Q2 | 1.93 Million USD | 3362.5% |
| 2021 Q1 | -1.1 Million USD | -505.46% |
| 2021 Q4 | 306 Thousand USD | -90.27% |
| 2021 Q3 | 3.14 Million USD | 37.16% |
| 2021 FY | 4.63 Million USD | 93.49% |
| 2021 Q2 | 2.29 Million USD | 306.95% |
| 2020 FY | 2.39 Million USD | 414.44% |
| 2020 Q3 | 1.62 Million USD | 0.0% |
| 2020 Q4 | -183 Thousand USD | -111.3% |
| 2019 FY | -762 Thousand USD | -37.55% |
| 2019 Q1 | -789 Thousand USD | -120.39% |
| 2019 Q2 | -605 Thousand USD | 23.32% |
| 2018 Q2 | 1.34 Million USD | 352.83% |
| 2018 Q1 | -530 Thousand USD | 2.03% |
| 2018 Q3 | -633 Thousand USD | -147.24% |
| 2018 FY | -554 Thousand USD | 67.02% |
| 2018 Q4 | -358 Thousand USD | 43.44% |
| 2017 Q1 | -380 Thousand USD | -17.28% |
| 2017 FY | -1.68 Million USD | -6.06% |
| 2017 Q3 | -545 Thousand USD | -154.67% |
| 2017 Q2 | -214 Thousand USD | 43.68% |
| 2017 Q4 | -541 Thousand USD | 0.73% |
| 2016 Q1 | -382 Thousand USD | 55.89% |
| 2016 Q2 | -377 Thousand USD | 1.31% |
| 2016 Q4 | -324 Thousand USD | 35.33% |
| 2016 FY | -1.58 Million USD | 46.1% |
| 2016 Q3 | -501 Thousand USD | -32.89% |
| 2015 Q3 | -416 Thousand USD | 50.18% |
| 2015 Q4 | -866 Thousand USD | -108.17% |
| 2015 Q1 | -822 Thousand USD | -1.48% |
| 2015 Q2 | -835 Thousand USD | -1.58% |
| 2015 FY | -2.93 Million USD | 35.04% |
| 2014 Q1 | -1.08 Million USD | -50.7% |
| 2014 Q2 | -1.39 Million USD | -28.84% |
| 2014 Q4 | -810 Thousand USD | 34.57% |
| 2014 Q3 | -1.23 Million USD | 11.19% |
| 2014 FY | -4.52 Million USD | -5.38% |
| 2013 Q2 | -1.02 Million USD | 23.72% |
| 2013 Q1 | -1.34 Million USD | 0.0% |
| 2013 Q4 | -718 Thousand USD | 40.32% |
| 2013 FY | -4.29 Million USD | 0.0% |
| 2013 Q3 | -1.2 Million USD | -17.25% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 5.948% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 75.102% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 92.962% |
| Nascent Biotech, Inc. | -2.22 Million USD | 43.674% |
| Rebus Holdings, Inc. | -664 Thousand USD | -89.157% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.534% |
| Qrons Inc. | -643.67 Thousand USD | -95.129% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -222.407% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.737% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -202.302% |
| Skye Bioscience, Inc. | -13.67 Million USD | 90.813% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.25% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 125.555% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -379.891% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.344% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 55.938% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 18.232% |
| Mesoblast Limited | -84.14 Million USD | 98.507% |
| Marizyme, Inc. | -34.08 Million USD | 96.315% |
| Genus plc | 6.4 Million USD | 119.625% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 112.892% |
| Pharming Group N.V. | -4.87 Million USD | 74.26% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 36.773% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -34.854% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 84.958% |
| ContraFect Corporation | -56.88 Million USD | 97.792% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 72.424% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 10.413% |
| IMV Inc. | -38.67 Million USD | 96.752% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 54.341% |
| MultiCell Technologies, Inc. | -722.81 USD | -173666.273% |
| ONE Bio Corp. | 13.68 Million USD | 109.18% |
| Accustem Sciences Inc. | -3.74 Million USD | 66.475% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.871% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -160.008% |
| Q BioMed Inc. | -3.44 Million USD | 63.548% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 135.48% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 52.198% |
| Biomind Labs Inc. | -1 Million USD | -24.405% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.715% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 56.708% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 81.107% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 32.631% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -4093.376% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 92.086% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 35.01% |
| GB Sciences, Inc. | -1.42 Million USD | 11.581% |
| Alpha Cognition Inc. | -9.7 Million USD | 87.059% |
| HST Global, Inc. | -140.9 Thousand USD | -791.368% |
| CSL Limited | 3.7 Billion USD | 100.034% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -11.654% |
| Halberd Corporation | -75.05 Thousand USD | -1573.551% |
| Enzolytics Inc. | -2.14 Million USD | 41.549% |
| Agentix Corp. | -1.37 Million USD | 8.439% |
| Resverlogix Corp. | -12.74 Million USD | 90.148% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 60.357% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.705% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -20.307% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 56.978% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 20.474% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 63.113% |
| AVAX Technologies, Inc. | 6.69 Million USD | 118.766% |
| Zenith Capital Corp. | -8.94 Million USD | 85.955% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.698% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -7109.689% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 48.846% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -632.321% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 37.349% |
| Kadimastem Ltd | -3.04 Million USD | 58.688% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -27.635% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 83.854% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -592.068% |
| LadRx Corporation | -3.82 Million USD | 67.152% |
| Cell Source, Inc. | -4.32 Million USD | 70.962% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -82.837% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -82.837% |
| NovAccess Global Inc. | -2.46 Million USD | 49.083% |
| Affymax, Inc. | -15.04 Million USD | 91.652% |
| Itoco Inc. | -919.14 Thousand USD | -36.649% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 70.366% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -12.243% |
| Mobile Lads Corp. | -554.55 Thousand USD | -126.49% |
| CytoDyn Inc. | -18.05 Million USD | 93.045% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -4890.068% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -470.707% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -122.41% |
| SYBLEU INC | -149.18 Thousand USD | -741.936% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 30.849% |
| International Stem Cell Corporation | -663 Thousand USD | -89.442% |
| Bioxytran, Inc. | -3.82 Million USD | 67.122% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2286.018% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -6075.025% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 96.537% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 22.373% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -70.69% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 59.627% |
| Neutra Corp. | -229.48 Thousand USD | -447.31% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 92.839% |
| PureTech Health plc | -146.19 Million USD | 99.141% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 94.156% |
| IXICO plc | -1.43 Million USD | 12.596% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 86.766% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.969% |
| CSL Limited | 3.81 Billion USD | 100.033% |
| Cellectis S.A. | -108.85 Million USD | 98.846% |